Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab Based on Efficacy Results
Decision not based on safety concerns; Phase 3 lupus program
continues as planned
INDIANAPOLIS,
Feb. 7, 2013 /PRNewswire/ -- Eli
Lilly and Company (NYSE:LLY) announced today that it will
discontinue the Phase 3 rheumatoid arthritis (RA)...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news